Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSGALNACT1 | Q8TDX6 | 13/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2298516 | 1.00 | CSGALNACT1 (0.49) | CSGALNACT1NPC1EPHX2SMN1; SMN2ALDH1A1 | |
| SCHEMBL2294419 | 0.91 | CSGALNACT1 (0.53) | CSGALNACT1 | |
| SCHEMBL2294429 | 0.91 | CSGALNACT1 (0.53) | CSGALNACT1 | |
| SCHEMBL2294441 | 0.87 | CSGALNACT1 (0.61) | CSGALNACT1 | |
| SCHEMBL2294446 | 0.87 | CSGALNACT1 (0.61) | CSGALNACT1 | |
| SCHEMBL2294568 | 0.84 | CSGALNACT1 (0.66) | CSGALNACT1ALDH1A1 | |
| SCHEMBL2294563 | 0.84 | CSGALNACT1 (0.66) | CSGALNACT1ALDH1A1 | |
| SCHEMBL2296693 | 0.81 | CSGALNACT1 (0.71) | CSGALNACT1 | |
| SCHEMBL2296698 | 0.81 | CSGALNACT1 (0.71) | CSGALNACT1 | |
| SCHEMBL2298936 | 0.81 | CSGALNACT1 (0.53) | CSGALNACT1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835428-B2 | Diacylglycerol acyltransferase inhibitors | Piramal Enterprises Limited (IN) | 2014-09-16 | — | — | US | claimed |
| US-20110196002-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED. | 2011-08-11 | — | — | US | claimed |
| WO-2010023609-A1 | OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-03-04 | — | — | WO | claimed |
| US-8835428-B2 | Diacylglycerol acyltransferase inhibitors | Piramal Enterprises Limited (IN) | 2014-09-16 | — | — | US | disclosed |
| US-20110196002-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED. | 2011-08-11 | — | — | US | disclosed |
| WO-2010023609-A1 | OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110196002-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, DLAT | CSGALNACT1 455/4885NPC1 436/4885EPHX2 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.